Sanofi logo SNY - Sanofi

Price: -- -- | CONSENSUS: Hold DETAILS
STRONG
BUY
0
BUY 12
HOLD 14
SELL 1
STRONG
SELL
0
| PRICE TARGET: $49.50 DETAILS
HIGH: $50.00
LOW: $49.00
MEDIAN: $49.50
CONSENSUS: $49.50
UPSIDE: 8.70%

About Sanofi (https://www.sanofi.com)

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Key Executives

NAME TITLE DOB SALARY
Belen Garijo Lopez Chief Executive Officer & Director 1960 $4,724,298 EUR
Erik Wallström Head of Therapeutic Area - Neurology Development
Fabrizio Gaudi Head of Austrian, German & Swiss Operations
François-Xavier Roger Executive Vice President & Chief Financial Officer 1962
Madeleine Roach Executive Vice President & Head of Business Operations 1984
Natalie Bickford Executive Vice President & Chief People Officer 1970
Olivier Charmeil Executive Vice President of General Medicines 1963
Pierre Chancel Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing 1957
Roy Papatheodorou Executive Vice President & General Counsel 1978
Thomas Kudsk Larsen Head of Investor Relations & General Medicines 1974
Thomas Triomphe Executive Vice President of Vaccines 1974

Company Peers

Peer analysis pending, check back in 1-2 minutes.